Taysha gene therapy GAN, TSHA-120 FDA feedback, Astellas Taysha gene therapy deal, Taysha pipeline update, GAN gene therapy challenges, Taysha Rett syndrome TSHA-102, Taysha stock price TSHA,

Taysha halts gene therapy for rare nerve disease after FDA and Astellas feedback

Anika Sharma

Astellas has declined the opportunity to exercise an option for an asset from Taysha Gene Therapies. Taysha, facing study design ...